| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8676304 | Revista Colombiana de Cardiología | 2017 | 9 Pages |
Abstract
Evolocumab and alirocumab, monoclonal antibodies against PCSK9, are very useful novel therapeutic tools in heterozygous familial hypercholesterolemia, some homozygous familial hypercholesterolemia cases, and in individuals with a high cardiovascular risk whose LDL-C levels cannot be controlled with maximum tolerated doses of highly effective statins, ezetimibe, and lifestyle changes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Álvaro J. Ruiz,